Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment

Jack, Clifford R.; Petersen, Ronald C.; Xu, Yue; O’Brien, Peter C.; Smith, Glenn E.; Ivnik, Robert J.; Boeve, Bradley F.; Waring, Stephen C.; Tangalos, Eric G.; Kokmen, Emre

doi:10.1212/wnl.52.7.1397

Cited by 1,291 publications

(937 citation statements)

References 42 publications

Supporting

Mentioning

846

Contrasting

Unclassified

Order By: Relevance

“…In addition, MCI subjects with greater hippocampal atrophy at baseline are more likely to convert to AD (Jack et al, 1999;Visser et al, 1999;Killiany 2000;Dickerson et al, 2001;Killiany et al, 2002;Adak et al, 2004;DeCarli et al, 2004). In this study however, hippocampal volumes at baseline in APOE ∈4 carriers treated with donepezil (5062 mm 3 , SD 773 mm 3 ) were not different from those treated with placebo (4916 mm 3 , SD 744) (p= 0.51) ( Table 1).…”

Section: Effect Of Treatment On Mri Atrophy Ratesmentioning

confidence: 50%

Longitudinal MRI findings from the vitamin E and donepezil treatment study for MCI

Jack

Petersen

Grundman³

et al. 2008

Neurobiology of Aging

133

View full text Add to dashboard Cite

The vitamin E and donepezil trial for the treatment of amnestic mild cognitive impairment (MCI) was conducted at 69 centers in North America; 24 centers participated in an MRI sub study. The objective of this study was to evaluate the effect of treatment on MRI atrophy rates; and validate rate measures from serial MRI as indicators of disease progression in multi center therapeutic trials for MCI. Annual percent change (APC) from baseline to follow-up was measured for hippocampus, entorhinal cortex, whole brain, and ventricle in the 131 subjects who remained in the treatment study and completed technically satisfactory baseline and follow-up scans. Although a non-significant trend toward slowing of hippocampal atrophy rates was seen in APOE ∈4 carriers treated with donepezil; no treatment effect was confirmed for any MRI measure in either treatment group. For each of the four brain atrophy rate measures, APCs were greater in subjects who converted to AD than non-converters, and were greater in APOE ∈4 carriers than non-carriers. MRI APCs and changes Disclosure Statement for AuthorsThe authors have no conflicts of interest to disclose. The industry sponsors had no role in the analysis or interpretation of these data nor in the content of the paper. Appropriate approval procedures were used concerning human subjects. NIH Public Access IntroductionThe vitamin E and donepezil clinical trial for the treatment of mild cognitive impairment (MCI) was conducted in 769 subjects at 69 centers in North America . The study was designed to determine whether the antioxidant vitamin E or donepezil, the only cholinesterase inhibitor available at the time the study was designed, would be effective at delaying the clinical progression of subjects with the amnestic form of MCI to the clinical diagnosis of Alzheimer's disease (AD). While vitamin E had no beneficial effect, donepezil reduced the risk of progression from amnestic MCI to clinically possible or probable AD for up to 12 months. This treatment effect was extended to 24 months in carriers of the apolipoprotein E ∈4 (APOE e4) allele. Twenty-four of the recruiting sites voluntarily participated in a Magnetic Resonance Imaging (MRI) sub study which was grafted onto the existing clinical therapeutic study design. The purpose of the MRI sub study was to determine if a therapeutic effect of either vitamin E or donepezil could be detected on rates of brain atrophy from serial MRI studies. Four different brain atrophy brain measures were assessed; the hippocampus, entorhinal cortex (ERC), whole brain, and ventricular volume. Each of these MRI measurements has figured prominently in anatomic MRI based studies of MCI, AD, and normal aging (Jack et al., 1992;Fox et al., 1996;Jack et al., 1997;Fox et al., 1999;Killiany 2000;Dickerson et al., 2001;Killiany et al., 2002;Du et al., 2003). A primary objective of this analysis was to test the hypothesis that vitamin E or donepezil slowed the rate of brain atrophy relative to placebo in subjects with amnestic MCI (Petersen 1995;Pe...

show abstract

Section: Effect Of Treatment On Mri Atrophy Ratesmentioning

confidence: 50%

Longitudinal MRI findings from the vitamin E and donepezil treatment study for MCI

Jack

Petersen

Grundman³

et al. 2008

Neurobiology of Aging

133

View full text Add to dashboard Cite

show abstract

“…Volumetric brain analyses by cerebral magnetic resonance imaging (MRI) have shown a close association between reduced hippocampal volume and cognitive impairment 5, 6. Yet, results from studies associating cardiac function with cerebral MRI findings are conflicting, with grey matter loss in the hippocampal regions related to LV dysfunction in some studies7 and not others 8, 9…”

Section: Introductionmentioning

confidence: 99%

Associations Between Left Ventricular Dysfunction and Brain Structure and Function: Findings From the SABRE (Southall and Brent Revisited) Study

Park

Williams

Chaturvedi

et al. 2017

JAHA

View full text Add to dashboard Cite

BackgroundSubclinical left ventricular (LV) dysfunction has been inconsistently associated with early cognitive impairment, and mechanistic pathways have been poorly considered. We investigated the cross‐sectional relationship between LV dysfunction and structural/functional measures of the brain and explored the role of potential mechanisms.Method and ResultsA total of 1338 individuals (69±6 years) from the Southall and Brent Revisited study underwent echocardiography for systolic (tissue Doppler imaging peak systolic wave) and diastolic (left atrial diameter) assessment. Cognitive function was assessed and total and hippocampal brain volumes were measured by magnetic resonance imaging. Global LV function was assessed by circulating N‐terminal pro–brain natriuretic peptide. The role of potential mechanistic pathways of arterial stiffness, atherosclerosis, microvascular disease, and inflammation were explored. After adjusting for age, sex, and ethnicity, lower systolic function was associated with lower total brain (beta±standard error, 14.9±3.2 cm3; P<0.0001) and hippocampal volumes (0.05±0.02 cm3, P=0.01). Reduced diastolic function was associated with poorer working memory (−0.21±0.07, P=0.004) and fluency scores (−0.18±0.08, P=0.02). Reduced global LV function was associated with smaller hippocampal volume (−0.10±0.03 cm3, P=0.004) and adverse visual memory (−0.076±0.03, P=0.02) and processing speed (0.063±0.02, P=0.006) scores. Separate adjustment for concomitant cardiovascular risk factors attenuated associations with hippocampal volume and fluency only. Further adjustment for the alternative pathways of microvascular disease or arterial stiffness attenuated the relationship between global LV function and visual memory.ConclusionsIn a community‐based sample of older people, measures of LV function were associated with structural/functional measures of the brain. These associations were not wholly explained by concomitant risk factors or potential mechanistic pathways.

show abstract

“…Regions of interest in the brain include substructures of the medial temporal lobe such as the hippocampus, amygdala and entorhinal cortex (Jack et al 1999;De Santi et al 2001;Hampel et al 2002;Chetelat and Baron 2003;de Leon et al 2006). Early AD is associated with neuronal loss and consequent changes in gray matter, which eventually leads to the atrophy of cortical gyri and widening of sulci.…”

Section: Introductionmentioning

confidence: 99%

T1ρ MRI of Alzheimer's disease

et al. 2008

View full text Add to dashboard Cite

Alzheimer's disease (AD) is the most common form of dementia in the elderly. Classic symptoms of the disease include memory loss and confusion associated with the hallmark neuro-pathologic lesions of neurofibrillary tangles (NFT) and senile plaques (SP) and their sequelae, gray matter atrophy. Volumetric assessment methods measure tissue atrophy, which typically follows early biochemical changes. An alternate MRI contrast mechanism to visualize the early pathological changes is T 1ρ (or "T-1-rho"), the spin lattice relaxation time constant in the rotating frame, which determines the decay of the transverse magnetization in the presence of a "spin-lock" radio-frequency field. Macromolecular changes (in plaques and tangles) that accompany early AD are expected to alter bulk water T 1ρ relaxation times. In this work, we measure T 1ρ MRI on patients with clinically diagnosed AD, MCI and in age-matched ognitively normal control subjects in order to compare T 1ρ values with changes in brain volume in the same regions of the brain and demonstrate that T 1ρ can potentially constitute an important biomarker of AD.

show abstract

Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment

Cited by 1,291 publications

References 42 publications

Longitudinal MRI findings from the vitamin E and donepezil treatment study for MCI

Longitudinal MRI findings from the vitamin E and donepezil treatment study for MCI

Associations Between Left Ventricular Dysfunction and Brain Structure and Function: Findings From the SABRE (Southall and Brent Revisited) Study

T1ρ MRI of Alzheimer's disease

Contact Info

Product

Resources

About